Genetic Signatures eyes $15M IPO to fuel international expansion; CombiMatrix rolls out genetic screening test for in vitro fertilization;

> Australian molecular diagnostics outfit Genetic Signatures announced plans for an estimated $15 million IPO to fuel expansion in the European and U.S. markets. Story (reg. req.)

> Molecular diagnostics maker CombiMatrix ($CBMX) launched its preimplantation genetic screening test for women undergoing in vitro fertilization. Release

> Stemina Biomarker Discovery snagged a $2.3 million investment from the Nancy Lurie Marks Family Foundation to fund its clinical study of blood biomarkers in children with autism spectrum disorders. Story (reg. req.)

> Foundation Medicine ($FMI) unveiled new data from its ongoing collaboration with Clovis Oncology ($CLVS) that shows that its companion diagnostic can identify both BRCA-mutant patients and non-BRCA-mutant patients who could benefit from Clovis' rucaparib. Release

> Genetic Technologies completed the sale of its Australian Genetics business to Specialist Diagnostics Services for $2 million in cash, furthering its plans to refocus on its U.S. molecular diagnostics business and beef up commercialization for its breast cancer risk test. More (reg. req.)

> Adarza BioSystems inked a supply and licensing agreement with Horizon Discovery, giving the company the exclusive right to offer research services on its Arrayed Imaging Reflectometry multiplex immunoassay technology. Story (reg. req.)

> Australian proteomics outfit Proteomics International Laboratories is weighing an IPO worth up to $5.2 million to drive growth in its diagnostics, therapeutics and analytical services units. More (reg. req.)

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.